Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension

Author:Giovannoni, Gavin   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Saubadu, Stephane   Bejuit, Raphael   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Vermersch, Patrick   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.007  

Author Institution:Queen Mary University of London, London, United Kingdom  University Hospital Basel and University of Basel, Basel, Switzerland  University of Michigan Medical Center, Ann Arbor, MI  University of Alabama at Birmingham (UAB) School of Public Health, Birmingham, AL  Dnipro State Medical University, Dnipro, Ukraine  Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria  St. Anne’s University Hospital, Brno, Czech Republic  Sanofi, Chilly Mazarin, France  Sanofi, Chilly-Mazarin, France  Sanofi, Cambridge, MA  Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  

The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Author:Mao-Draayer, Yang   Rammohan, Kottil   Li, David   Halper, June   McCurdy Murphy, Sara   Brown, Audrey   Wilkerson, Jesse   Patton, Lisa   Bratcher, Briana   

Session Name:P11: Multiple Sclerosis: Epidemiology and Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:P11.002  

Author Institution:University of Michigan, Department of Neurology, Ann Arbor, MI  University of Miami, MIAMI, FL  University of British Columbia, Vancouver, BC, Canada  CMSC, Hackensack, NJ  DLH Corp, Silver Spring, MD  DLH Corp, Durham, NC